Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs

Leuk Res. 2021 Feb:101:106499. doi: 10.1016/j.leukres.2020.106499. Epub 2020 Dec 31.

Authors

Konstantin Byrgazov¹, Marianne Kraus², Andrej Besse², Ana Slipicevic³, Fredrik Lehmann³, Christoph Driessen², Lenka Besse⁴

Affiliations

¹ Oncopeptides AB, Stockholm, Sweden. Electronic address: konstantin.byrgazov@oncopeptides.com.
² Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Switzerland.
³ Oncopeptides AB, Stockholm, Sweden.
⁴ Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Switzerland. Electronic address: lenka.besse@kssg.ch.

PMID: 33422770
DOI: 10.1016/j.leukres.2020.106499

No abstract available

Keywords: Drug resistance; MDR1; Myeloma; Proteasome inhibitors.

Publication types

Review

MeSH terms

ATP Binding Cassette Transporter, Subfamily B / biosynthesis
Drug Resistance, Multiple / drug effects*
Drug Resistance, Neoplasm / drug effects*
Gene Expression Regulation, Neoplastic / drug effects*
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / metabolism
Multiple Myeloma* / pathology
Neoplasm Proteins / biosynthesis*
Oligopeptides / therapeutic use*
Up-Regulation / drug effects*

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
Neoplasm Proteins
Oligopeptides
carfilzomib